United Therapeutics Corp
UTHR
$519.01
+0.06%
United Therapeutics Corp is a biotechnology company focused on developing and commercializing innovative therapies for pulmonary arterial hypertension (PAH), a rare and progressive disease characterized by high blood pressure in the lungs' arteries. The company's portfolio includes Tyvaso DPI, Remodulin, Orenitram, Adcirca, and Unituxin, with Tyvaso DPI being the primary revenue driver. United Therapeutics holds a dominant position in the PAH market, leveraging its expertise in the prostacyclin pathway to maintain a competitive edge. The current investor narrative centers on the potential expansion of Tyvaso into new indications, as positive Phase 3 data for a new lung disease has fueled optimism about significant market growth and a major FDA filing, while the stock's strong performance over the past year reflects confidence in its growth trajectory.…
UTHR
United Therapeutics Corp
$519.01
Related headlines
Investment Opinion: Should I buy UTHR Today?
Based on the analysis, UTHR is rated a Buy. The thesis is that UTHR's exceptional profitability, discounted valuation, and strong analyst support, combined with the potential Tyvaso expansion, offer a favorable risk-reward profile. The consensus recommendation is 'Buy' with an average price target of $663.23, implying 28.1% upside from the current price of $517.71.
Sign up to view all
UTHR 12-Month Price Forecast
The AI assessment is bullish with medium confidence. UTHR's valuation is attractive relative to its profitability, and the Tyvaso expansion is a significant catalyst that could drive growth. However, the flat revenue trend and regulatory uncertainty temper confidence. If the FDA approves Tyvaso and revenue growth resumes, the stance would be upgraded to high confidence. Conversely, a rejection or continued stagnation would lead to a downgrade to neutral or bearish.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on United Therapeutics Corp's 12-month outlook, with a consensus price target around $663.23 and implied upside of +27.8% versus the current price.
Average Target
$663.23
0 analysts
Implied Upside
+27.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$516 - $750
Analyst target range
United Therapeutics is covered by 13 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 1.6 (where 1 is Strong Buy and 5 is Sell). The average price target is $663.23, implying a substantial upside of 28.1% from the current price of $517.71. The analyst sentiment is bullish, with no Sell ratings and a majority of Buy or Outperform ratings, reflecting confidence in the company's growth prospects, particularly the potential Tyvaso expansion. The target price range spans from $516.00 to $750.00, with the low end near the current price, suggesting some analysts see limited downside, while the high end implies a 44.9% upside. The wide spread between low and high targets indicates significant uncertainty about the company's future, likely tied to regulatory decisions and market adoption of Tyvaso in new indications. Recent ratings actions have been mixed, with Wells Fargo upgrading to Overweight in May 2026, while B of A Securities maintained a Neutral stance, indicating a divergence in opinion among analysts.
Bulls vs Bears: UTHR Investment Factors
UTHR presents a compelling bull case driven by exceptional profitability, a discounted valuation, and a strong analyst consensus, with the Tyvaso expansion as a potential growth catalyst. However, the bear case highlights revenue stagnation, high product concentration, and recent price weakness, suggesting the market is cautious about near-term growth. Currently, the bull case has stronger evidence, as the valuation discount and analyst targets imply significant upside, but the key tension lies in whether Tyvaso's new indication can reignite growth. If the FDA filing succeeds and revenue accelerates, the stock could re-rate higher; if it fails or is delayed, the stock may remain range-bound or decline.
Bullish
- Exceptional profitability metrics: UTHR boasts a net margin of 41.94% and an operating margin of 47.67%, far exceeding biotech industry norms. This indicates strong pricing power and operational efficiency, supporting a premium valuation.
- Undervalued relative to sector: With a trailing PE of 16.17x versus the biotech industry average of ~20x, UTHR trades at a 19% discount. This suggests the market is not fully pricing in its growth potential, especially with Tyvaso expansion.
- Strong analyst conviction: 13 analysts rate UTHR a 'Buy' with a mean score of 1.6 (1=Strong Buy), and the average price target of $663.23 implies 28.1% upside from $517.71. No Sell ratings indicate broad confidence.
- Tyvaso expansion catalyst: Positive Phase 3 data for Tyvaso in a new lung disease could lead to a major FDA filing, potentially opening a significant new market. This is a key growth driver beyond the current PAH indication.
Bearish
- Revenue stagnation: Q1 2026 revenue of $781.5M declined 1.62% YoY from $794.4M, breaking a growth streak. This suggests the core PAH market is maturing, and without Tyvaso expansion, growth may remain flat.
- High product concentration: Tyvaso accounts for 58.5% of total revenue ($457.5M of $781.5M). This concentration exposes UTHR to significant risk if Tyvaso faces competition, pricing pressure, or regulatory setbacks.
- Recent price momentum reversal: The stock has fallen 5.38% in the last month and 9.24% in the last three months, underperforming the S&P 500. This suggests profit-taking after a 88.46% run over the past year, potentially signaling a short-term correction.
- Valuation near historical midpoint: The current PE of 16.17x is near the midpoint of its 5-year range (8.75x-24.14x). While not overvalued, it offers limited margin of safety if growth disappoints, as the market may re-rate lower.
UTHR Technical Analysis
United Therapeutics has exhibited a robust long-term uptrend, with the stock price surging 88.46% over the past year, significantly outperforming the S&P 500's 18.19% gain. Currently trading at $517.71, the stock is positioned at 84.9% of its 52-week range (between $283.01 low and $609.35 high), indicating it remains near the higher end of its historical band. This suggests strong momentum and investor confidence, though it also implies the stock may be susceptible to profit-taking after such a substantial run. The 52-week low of $283.01 and high of $609.35 provide clear reference points for assessing support and resistance levels.
Beta
0.56
0.56x market volatility
Max Drawdown
-13.5%
Largest decline past year
52-Week Range
$292-$609
Price range past year
Annual Return
+70.3%
Cumulative gain past year
| Period | UTHR Return | S&P 500 |
|---|---|---|
| 1m | -5.2% | +2.5% |
| 3m | -8.8% | +5.2% |
| 6m | +6.9% | +11.5% |
| 1y | +70.3% | +22.6% |
| ytd | +4.5% | +12.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
UTHR Fundamental Analysis
United Therapeutics reported revenue of $781.5 million for Q1 2026, representing a slight year-over-year decline of 1.62% from $794.4 million in Q1 2025. This marks a deceleration from the previous quarters, where revenue grew from $714.9 million in Q2 2024 to $799.5 million in Q3 2025, but has since plateaued. The company's revenue is heavily concentrated in Tyvaso, which generated $457.5 million in the latest quarter, accounting for 58.5% of total revenue, while Remodulin and Orenitram contributed $126.6 million and $135.6 million, respectively. The slight dip in revenue suggests a mature product portfolio, but the potential expansion of Tyvaso into new indications could reignite growth.
Quarterly Revenue
$781500000.0B
2026-03
Revenue YoY Growth
-1.6%
YoY Comparison
Gross Margin
82.9%
Latest Quarter
Free Cash Flow
$1.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is UTHR Overvalued?
Given United Therapeutics' strong profitability, the price-to-earnings (PE) ratio is the most appropriate valuation metric. The trailing PE stands at 16.17x, while the forward PE is slightly lower at 15.67x, indicating that the market expects modest earnings growth. The gap between trailing and forward PE is narrow, suggesting stable earnings expectations. Compared to the biotechnology industry average PE of around 20x (based on available data), United Therapeutics trades at a discount of approximately 19%, which may reflect concerns about revenue stagnation or competitive pressures. However, the company's robust net margin of 41.94% and operating margin of 47.67% are exceptional, justifying a premium to the sector. Historically, the stock's PE has ranged from 8.75x in Q1 2024 to 24.14x in Q4 2022, and the current 16.17x is near the midpoint, suggesting the stock is fairly valued relative to its own history.
PE
16.2x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 9x~15x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are moderate but notable. UTHR's revenue declined 1.62% YoY in Q1 2026, indicating a mature product portfolio with limited organic growth. The company's heavy reliance on Tyvaso (58.5% of revenue) creates concentration risk; any disruption to Tyvaso's supply chain, pricing, or competitive position could significantly impact earnings. However, the balance sheet is fortress-like with a debt-to-equity ratio of 0.0053 and a current ratio of 6.60, providing ample liquidity to weather operational challenges. The net margin of 41.94% is exceptional, but it also means that any cost inflation or pricing pressure could disproportionately affect profitability.